The invention relates to the use of erucic acid (or cis- 13-docosenoic acid, 22:1 n-9) as a pharmaceutical or dietary supplement, to be administered for example in liposomes, for the prevention and treatment of ischemic heart disease, and for the prevention of thrombotic disorders and protlrombotic diathesis in general. The invention also relates to diagnostic methods involving the evaluation of blood concentrations of emcic acid as a diagnostic and prognostic biomarker in cardiovascular diseases and thrombotic disorders.
Treatment and prophylaxis of cardiovascular disorders with erucic acid and related diagnostic methods
Martinelli NicolaPrimo
;Bernardi Francesco;Baroni Marcello;
2020
Abstract
The invention relates to the use of erucic acid (or cis- 13-docosenoic acid, 22:1 n-9) as a pharmaceutical or dietary supplement, to be administered for example in liposomes, for the prevention and treatment of ischemic heart disease, and for the prevention of thrombotic disorders and protlrombotic diathesis in general. The invention also relates to diagnostic methods involving the evaluation of blood concentrations of emcic acid as a diagnostic and prognostic biomarker in cardiovascular diseases and thrombotic disorders.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
